In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain their CEOs, focusing instead on reshaping management at other levels. Companies like Bayer underwent sweeping transformations, while others, such as Pfizer, made targeted adjustments under investor scrutiny. Meanwhile, the rise of Artificial Intelligence prompted the creation of new ‘Chief AI Officer’ roles, the industry’s leading trade body welcomed a fresh leader, and one of European biotech’s most influential figures finally stepped into retirement after a storied career.

 

Big Pharma CEOs Stay Put

For the most part, in 2024 Big Pharma held onto their CEOs, many of whom, including GSK’s Emma Walmsley and Novartis’ Vas Narasimhan, have been in place for over five years. In contrast to the leadership shifts in 2023 at pharma giants Bayer, BMS, and Roche Pharma, AbbVie was last year’s exception among Big Pharma.

The CEO change at AbbVie was also exceptional since the new chief executive officer is only the second in the company’s entire history. Since its inception in 2013, AbbVie had always been led by Richard A. Gonzalez until former president and chief operating officer Robert A. Michael was named last February. The announcement came at a time when the company was still weathering the loss of US exclusivity for its blockbuster Humira.

 

Pfizer Contests Investor Pressure

Last year, some leadership decisions were also made under pressure. Coming under fire from investors, namely activist hedge fund Starboard Value’s chief executive officer, who claimed the board needed to hold management accountable for its underperformance last year, Pfizer appointed a new chief scientific officer and head of research and development.

Chris Boshoff was moved into the position, replacing long-standing chief scientific officer Mikael Dolsten, from his role as leader of Pfizer’s oncology division where he was instrumental in the firm’s acquisition of Seagen. The decision was seen as a crucial test for CEO Albert Bourla, who has recently been criticized for delivering low shareholder returns. With a market value of USD 142 billion, Pfizer has had a downturn of over 58 percent since its COVID-19 vaccine heydays and has seen its share price descend by 15.6 percent.

Boshoff is “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential,” Bourla said in a statement.

 

Shakeup at Bayer

When Bill Anderson came onboard as CEO of Bayer in 2023, he vowed to restructure the ailing company, still suffering from the burden of lawsuits against its crop science division resulting from the acquisition of Monsanto. Last year he followed through on his promises and after cutting over 3,000 jobs at the beginning of the year as part of a “dynamic shared ownership” scheme to increase efficiency, Bayer revealed a plan to cut its investor dividends over the next three years to help reduce the company’s colossal debt.

In a further move to cut costs, Anderson streamlined the leadership team of Bayer’s pharma division in March, taking it from 14 to eight. Sebastian Guth was named as Chief Operating Officer (COO) and tasked with driving the company’s commercial strategy. In addition, a “Global Commercialization” organization was created with new leader Christine Rothto at the helm. “We have decided to dismantle our traditional model with functional silos and many layers of hierarchy. We are replacing it with our new operating model, which has Product and Customer Teams at its center,” said Stefan Oelrich, president of Bayer’s Pharmaceuticals Division.

 

AI Push Drives New Leadership Roles

It’s no secret that life sciences companies have made a firm bet on Artificial Intelligence (AI), using the technology in processes that range from drug discovery to marketing, but in 2024 the importance of AI was further confirmed at Eli Lilly. The company created the position of chief artificial intelligence officer, appointing Thomas Fuchs, former dean and department chair for AI and human health at Mount Sinai.

Pharma companies have long been convinced of AI’s potential and have increasingly tasked dedicated leaders to steer their AI initiatives. While drugmakers’ AI efforts have typically been led by chief digital officers, a role which has come to prominence over the past decade, Lilly is not the only company to appoint an AI lead. In August, Pfizer named Berta Rodriguez-Hervas as its chief AI and analytics officer, whereas Merck appointed Chief Data & AI Officer Walid Mehanna almost three years ago.

 

An Industry Stalwart Departs

Other big industry leadership news last year was the departure of Thomas Cueni from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Having led the industry’s largest global trade group for seven years, Cueni took his leave to retire. With a legacy that includes coordinating innovative pharma’s successful response to the COVID-19 pandemic, Cueni was a much-admired figure.

For Pfizer CEO and then president of the IFPMA Albert Bourla, Cueni made and important impact during his tenure “with initiatives such as Access Accelerated, the successful creation of the AMR Action Fund, and most recently the Berlin Declaration, the industry’s commitment to more equitable rollout of medical countermeasures in a future pandemic.”

Former CEO of Medicines for Malaria Ventures (MMV) and scientist with a 30-plus year track record, David Reddy took over as the new director general and is tasked with ensuring a fair deal for industry within the WHO Pandemic Agreement.

 

A Biotech Legend Steps Down

European biotech lost one of its leading lights when Jean-Paul Clozel stepped down last year from his role as CEO after seven years heading up Basel, Switzerland-headquartered Idorsia. A follow up to Actelion, the company he founded along with wife Martine Clozel in 1997 and that went on to launch no less than three blockbuster drugs and get snapped up by Johnson & Johnson in 2017, Idorsia was a rebranded spinoff of Actelion’s drug discovery and early clinical pipeline business.

“It has been an absolute privilege to serve as CEO of Actelion and Idorsia for the past 24 years,” said Clozel.  “I can think of no greater endeavor than discovering new medicines that help patients lead better lives. I’ve been very fortunate to work alongside some amazing people from all disciplines and together, we have achieved more than I could have ever imagined when I started out in my research career.”

Taking over from Clozel is André C. Muller who has served as the company’s Chief Financial Officer (CFO) since its foundation and has taken the lead on many of the company’s business development initiatives.